AbbVie Gains 4.4% in 5 Days as $8.8 Billion Immunology Sales Drive Independence

2 articles · Updated · Trefis · Aug 21

AbbVie rose 4.4% over the last five trading days even as the S&P 500 fell 2.0%, extending a pattern of stock moves driven more by company-specific developments than by the broader market.
A 0.22 five-year correlation with the S&P 500 reflects that profile, with nearly $8.8 billion of second-quarter 2026 revenue coming from immunology, including $5.5 billion from Skyrizi and more than $2.5 billion from Rinvoq.
Recent catalysts have been regulatory as well as commercial: the European Commission approved Rinvoq for non-segmental vitiligo in late July, and the FDA accepted a filing for Botox Cosmetic in masseter muscle prominence in early August.
That independence does not mean stability—AbbVie posted a 21.5% annualized five-year return with 23.5% volatility, versus 12.9% and 17.2% for the S&P 500.
Investors now face a key pipeline test before year-end 2026, when AbbVie expects 16-week Phase III hidradenitis suppurativa data for Rinvoq and lutikizumab.